UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.		
10/726,952	12/03/2003	Roy Schoenberg	TZG0005	4379	
	7590 05/27/201 g LLP (Trizetto Custor	EXAMINER			
ATTN: Dawn-N	Marie Bey	SHIFERAW, ELENI A			
1700 Pennsylvania Avenue N.W. Suite 200 Washington, DC 20006			ART UNIT	PAPER NUMBER	
			2436		
			NOTIFICATION DATE	DELIVERY MODE	
			05/27/2010	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jpaollella-bald@kslaw.com dbey@kslaw.com mblasik@kslaw.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/726,952	SCHOENBERG, ROY		
Examiner	Art Unit		
	AILOIIIL		

	ELENI A. SHIFERAW	2436	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>11 May 2010</u> FAILS TO PLACE THIS APPI			
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperor Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of A eplies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this Arno event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (IMONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	ter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejectio	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in completing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with AMENDMENTS 	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be	out prior to the date of filing a brief	will not be entered be	Called
(a) They raise new issues that would require further cor	· · · · · · · · · · · · · · · · · · ·		cause
(b) ☐ They raise the issue of new matter (see NOTE below			
(c) ☐ They are not deemed to place the application in bett appeal; and/or	er form for appeal by materially red	ducing or simplifying th	ne issues for
(d) ☐ They present additional claims without canceling a c	orresponding number of finally reje	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s):		mpliant Amendment (F	PTOL-324).
6. Newly proposed or amended claim(s) would be all		timely filed amendmer	t canceling the
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov		l be entered and an ex	xplanation of
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>1-22, 24-28, and 30-38, 40 and 44</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE	. la - f - u - u - u - t la - u - t - u - f f l'u - u - N la		h
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attache	ed.
11. The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowand	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (13. Other:	PTO/SB/08) Paper No(s)		
	/Eleni A Shiferaw/ Primary Examiner, Art U	nit 2436	

Continuation of 11. does NOT place the application in condition for allowance because: THE 112 1ST REJECTION TO CLAIMS 30-36 IS MAINTAINED SINCE THE CLAIMS (CLAIM 30 LAST LIMITATION) RECITES THE UNSUPPORTED LIMITATION. The examiner withdraws the 112 1st paragraph rejection in view of applicants CANCELED claims 39 and 41-43.

Regarding argument the obviousness type double patenting claims 2 and 5 not disclosing generating second level access of the first level access key, is certainly not persuasive because 10726423 does recite the generation of the second level access of the first level access key. The claims on 10726423 recite generating a first key that grants a patient-defined level of access to a first set of medical records, generating a second access key that grants a second set of medical records, wherein the first and second keys are associated (see claims 1, 2, 3, and 5). It would have been obvious to one ordinary skill in the art to understand clearly that these limitations are equivalent as argued and rejected before.

Regarding argument the references failure to teach "generating a second-level access key ... by modifying the level of access of the first access key" argument is not persuasive because Kohane et al. discloses the patient is controlling his own medical record (portion or all) by modifying and providing different roles/rights to different agents/doctors/health institutes (see par. 46-61, and 13). Kohane et al. further teaches the document owner i.e. the patient/creator/individual (par. 37, 40, and 5-8) selecting confidential/medical records of his own and controlling the selected portions of his own medical record (par. 49-55) by providing different tokens to different health institutions and doctors (par. 7, and 49-53) by specifying access rights/roles (see par. 55-61 and fig. 3-6B). However Kohane et al. fails to explicitly disclose generating the second-level key by modifying the first level key.

Knapton, III discloses that generation of a password from first and second key (see col. 2 lines 24-43) and further discloses that password is generated from different information (see col. 2 lines 24-43). The examiner sufficiently provided motivation to combine references AND CLEAR articulation of the reasons why the claims are obvious. It is obvious to generate a second key from almost everything as also the argued limitation is disclosed in Knapton and/or the combination of the references teach every single limitation recited.